Vivos Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $7.66 million
- Book Value:
- Revenue TTM:
- $15.45 million
- Operating Margin TTM:
- Gross Profit TTM:
- $12.60 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Vivos Therapeutics Inc had its IPO on 2020-12-11 under the ticker symbol VVOS.
The company operates in the Healthcare sector and Medical Devices industry. Vivos Therapeutics Inc has a staff strength of 154 employees.
Shares of Vivos Therapeutics Inc opened at $0.26 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.25 - $0.26, and closed at $0.25.
This is a -1.6% slip from the previous day's closing price.
A total volume of 86,840 shares were traded at the close of the day’s session.
In the last one week, shares of Vivos Therapeutics Inc have slipped by -3.91%.
Vivos Therapeutics Inc's Key Ratios
Vivos Therapeutics Inc has a market cap of $7.66 million, indicating a price to book ratio of 0.4303 and a price to sales ratio of 0.4695.
In the last 12-months Vivos Therapeutics Inc’s revenue was $15.45 million with a gross profit of $12.60 million and an EBITDA of $-20323000. The EBITDA ratio measures Vivos Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vivos Therapeutics Inc’s operating margin was -135.87% while its return on assets stood at -68.82% with a return of equity of -221.35%.
In Q2, Vivos Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 18.9%.
Vivos Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vivos Therapeutics Inc’s profitability.
Vivos Therapeutics Inc stock is trading at a EV to sales ratio of 0.0765 and a EV to EBITDA ratio of 0.2893. Its price to sales ratio in the trailing 12-months stood at 0.4695.
Vivos Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $13.75 million
- Total Liabilities
- $8.44 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Vivos Therapeutics Inc ended 2023 with $13.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $13.75 million while shareholder equity stood at $2.11 million.
Vivos Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $8.44 million in other current liabilities, 3000.00 in common stock, $-86699000.00 in retained earnings and $2.84 million in goodwill. Its cash balance stood at $3.94 million and cash and short-term investments were $3.94 million. The company’s total short-term debt was $447,000 while long-term debt stood at $0.
Vivos Therapeutics Inc’s total current assets stands at $5.34 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $327000.00 compared to accounts payable of $1.33 million and inventory worth $0.
In 2023, Vivos Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $245000.
Comparatively, Vivos Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Vivos Therapeutics Inc stock is currently trading at $0.25 per share. It touched a 52-week high of $2.25 and a 52-week low of $2.25. Analysts tracking the stock have a 12-month average target price of $1.8.
Its 50-day moving average was $0.32 and 200-day moving average was $0.53 The short ratio stood at 0.28 indicating a short percent outstanding of 0%.
Around 1693.4% of the company’s stock are held by insiders while 1669.1% are held by institutions.
Frequently Asked Questions About Vivos Therapeutics Inc
Similar Industry Stocks (Medical Devices)
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.